Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InterAACT anal cancer chemotherapy comparison
ACTRN12616000061437Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jan 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in anal squamous cell carcinoma (SCCA) comparing Carboplatin + paclitaxel with Cisplatin + 5-fluorouracil (2 arms). Primary endpoint: Best overall response rate. Started Jan 2017; status: completed.
02
Drugs
carboplatinpaclitaxelcisplatinfluorouracil
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on ACTRN12616000061437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000061437.